ESPR - NASDAQ
Esperion Therapeutics, Inc.
$3.14
+0.32%Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
At a Glance
Live SnapshotEsperion Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Esperion Therapeutics, Inc. Income Statement
ESPR • NASDAQ
| Esperion Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2002 | Dec 2001 | Dec 2000 | Dec 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||||||
403.1M | 332.3M | 116.3M | 75.5M | 78.4M | 227.5M | 148.4M | 184.5M | 0.0 | 0.0 | 0.0 | 0.0 | 5B | 0.0 | 0.0 | 0.0 | 0.0 | 2K | 0.0 | |
GROSS PROFIT | |||||||||||||||||||
(129.2M) | (68.6M) | (43.3M) | (27M) | (14.2M) | (2.4M) | (0.0) | (265K) | (258K) | (252K) | (236K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (786K) | (683.2K) | |
273.9M | 263.7M | 73.1M | 48.5M | 64.2M | 225.2M | 148.4M | 184.2M | -258K | -252K | -236K | 0.0 | 5B | 0.0 | 0.0 | 0.0 | 0.0 | -784K | -683.2K | |
OPERATING INCOME | |||||||||||||||||||
(213.6M) | (209.3M) | (228.6M) | (228M) | (291M) | (346.6M) | (241.5M) | (204.6M) | (169M) | (76.2M) | (50M) | (36.2M) | (22.8M) | (10.2M) | (10.2M) | (29.2M) | (29.3M) | (26.8M) | (11.7M) | |
(165.8M) | (163.1M) | (142.5M) | (109.1M) | (185M) | (199.6M) | (65.9M) | (33.1M) | (21.4M) | (18.3M) | (20.2M) | (10.9M) | (6.7M) | (2.2M) | (2.4M) | (6M) | (5M) | (2.9M) | (2.5M) | |
(47.9M) | (46.2M) | (86.1M) | (118.9M) | (106M) | (146.9M) | (175.6M) | (171.5M) | (147.6M) | (57.9M) | (29.8M) | (25.3M) | (16M) | (8M) | (7.8M) | (22M) | (21.5M) | (21.8M) | (8.5M) | |
60.3M | 54.4M | -155.6M | -179.5M | -226.7M | -121.4M | -93.1M | -204.6M | -169M | -76.2M | -50M | -36.2M | -22.8M | -10.2M | -10.2M | -27.9M | -27.3M | -27.6M | -12.4M | |
PRE-TAX INCOME | |||||||||||||||||||
(84.6M) | (59.3M) | (59M) | (56.8M) | (46.4M) | (22.7M) | (8.1M) | (100K) | (198K) | (376K) | (520K) | (270K) | (936.6K) | (1.5M) | (577.2K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-81.1M | -59.3M | -59M | -56.8M | -46.4M | -22.7M | -8.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (119K) | (194K) | -83.6K | -75.8K | (0.0) | (0.0) | (5M) | (3.2M) | |
-81.1M | -106.1M | -53.7M | -54.2M | -42.4M | -22.2M | -4.1M | 2.8M | 2M | 1.2M | 256K | -151K | -3.3M | -1.5M | -653K | -780K | 2.4M | -3.8M | 0.0 | |
-20.8M | -51.7M | -209.2M | -233.7M | -269.1M | -143.6M | -97.2M | -201.8M | -167M | -75M | -49.8M | -36.4M | -26.1M | -11.7M | -10.8M | -28.7M | -24.9M | -31.4M | 0.0 | |
NET INCOME | |||||||||||||||||||
(1.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (229K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (4.1M) | -331.8K | |
-22.7M | -51.7M | -209.2M | -233.7M | -269.1M | -143.6M | -97.2M | -201.8M | -167M | -75M | -49.8M | -36.4M | -26.1M | -11.7M | -10.8M | -28.7M | -24.9M | -27.6M | -10.7M |
SEC Filings
ESPR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | May 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 11, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your ESPR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.